AstraZeneca

Pillar Biosciences partners with AstraZeneca to enhance access to NGS-based liquid biopsy tumor profiling, focusing on European markets. The collaboration aims to provide rapid, affordable testing solutions for detecting genetic cancer variants, leveraging Pillar's oncoReveal™ panels for cfDNA and cfRNA analysis, enabling local labs to deliver results within days.

TROP2 protein in NSCLC predicts better outcomes with datopotamab deruxtecan (dato-DXd) vs. docetaxel, per TROPION-Lung01 trial analysis. Dato-DXd reduced progression risk by 43% in TROP2-QCS biomarker-positive patients vs. 25% overall, with no new safety concerns. AstraZeneca and Roche Tissue Diagnostics plan to co-develop a TROP2-QCS biomarker companion diagnostic.

Nivolumab plus gemcitabine/cisplatin chemotherapy significantly improved response rates, overall survival, and progression-free survival in patients with lymph node–only metastatic urothelial carcinoma, according to a post hoc analysis of the CheckMate 901 trial presented at the 2024 ASCO Annual Meeting.

Brazil hosts over 400 cancer drug clinical trials, leveraging its diverse population and advanced healthcare infrastructure. The country's regulatory framework, led by ANVISA, has improved but still faces delays due to dual approvals. Despite challenges like limited funding and logistical issues, Brazil's commitment to enhancing its clinical trial ecosystem positions it as a key player in global medical research.

TROPION-Lung01 trial results show datopotamab deruxtecan (12.9 months OS) vs. docetaxel (11.8 months OS) in overall population, with nonsquamous histology showing 14.6 months vs. 12.3 months OS. In patients with actionable genomic alterations, datopotamab deruxtecan showed 15.6 months OS compared to 9.8 months with docetaxel. NeoCOAST-2 trial preliminary results indicate 34.1% pCR and 65.9% mPR with datopotamab deruxtecan plus Imfinzi and carboplatin in early-stage NSCLC.

Datopotamab deruxtecan showed a median overall survival of 14.6 months in patients with advanced nonsquamous non-small cell lung cancer in the TROPION-Lung01 Phase III trial. The trial, evaluating AstraZeneca and Daiichi Sankyo's drug versus chemotherapy, met the dual primary endpoint of progression-free survival. Results were presented at the IASLC 2024 World Conference on Lung Cancer.

Johnson & Johnson's Rybrevant and Lazcluze combo showed a 23% OS benefit over AstraZeneca's Tagrisso in advanced non-small cell lung cancer, with 61% survival at three years versus 53%. The combo also reduced CNS disease risk by 18% and received FDA approval for EGFR-mutated NSCLC.

IMFINZI is indicated for various lung cancer treatments, including unresectable Stage III NSCLC, metastatic NSCLC, extensive-stage SCLC, and biliary tract cancer. It also treats unresectable HCC in combination with IMJUDO. TROPION-Lung01 and NeoCOAST-2 are Phase III and II trials evaluating datopotamab deruxtecan and IMFINZI, respectively, in lung cancer. AstraZeneca collaborates with Daiichi Sankyo for ADC development and aims to improve lung cancer outcomes.